Innovation and Commercialization Center (ICC)
Established in partnership with Greater Louisville Inc., Louisville's Chamber of Commerce, the Kentucky Cabinet for Economic Development, the Kentucky Science & Technology Corporation and the Office of Commercialization & Innovation, an ICC office is located at Nucleus and assists early stage, technology-based companies with the commercialization of their product or service. The group exposes its clients to a wide variety of tools, resources and partners that keep emerging tech companies on a fast-growth track, often culminating in the successful securing of capital from private or public sources.
International Center for Long Term Care Innovation (InnovateLTC)
Nucleus is a key partner in the development of, and location for, the International Center for Long Term Care Innovation, an organization whose goal is to transform the global aging population by accelerating innovation and supporting entrepreneurial research and commercialization efforts.
MetaCyte Business Lab (MetaCyte)
MetaCyte Business Lab, a for-profit subsidiary of the UofL foundation, is a unique and vibrant health and life science incubator. Working with the University of Louisville's Office of Technology Transfer and Nucleus, MetaCyte is creating a seamless commercialization process that will yield viable, operating companies with a combined value in excess of $1B by 2020. In partnership with the inventor and co-founder, MetaCyte creates, launches, and manages portfolio companies, acquiring an equity position in each. By avoiding a fee-for-service model, precious capital is freed up and directed towards company growth.
Advanced Cancer Therapeutics (ACT)
Advanced Cancer Therapeutics is focused on the discovery and early development of novel cancer therapeutics as well as selection for partnership, commercialization and manufacture of the most promising discoveries. Utilizing its groundbreaking business arrangement with the James Graham Brown Cancer Center and the University of Louisville Research Foundation, ACT establishes rights to specific novel therapeutics and fast-tracks these leading edge discoveries to the pharmaceutical industry, and ultimately the patients who need them.
Institute for Strategic Biotechnology, Healthcare and Training (ISBHT)
Rapidly advancing innovations in biomedical and information technologies have generated unprecedented potential for advancing the translation of basic discoveries into diagnostics and therapeutics. Many recent interdisciplinary health technologies such as biomarkers have resulted in rapid breakthroughs in diagnostics and therapeutics, which are embracing these innovative preventive and treatment paradigms.
One of the major efforts of the Institute is to advance these preventive and treatment paradigms. Over the past few years, the Institute has been active in promoting this vision at the global level. The Institute has focused on areas that involve specific programs, training, technology transfer and personalized medicine concepts in healthcare delivery. The founders believe in fostering partnership with organizations and individuals, advancing the Institute’s goals and mission.